Skip to main content
. 2022 Dec 3;14(12):2706. doi: 10.3390/pharmaceutics14122706

Table 5.

In Vitro tested NLC-based TKI formulations.

TKI Ingredients Particle Size Tested Human Cancer Cell Lines Benefits Refs.
erlotinib Precirol®, Miglyol®, poloxamer 407 ca. 109 nm lung adenocarcinoma A549 cells ↑ cellular uptake
apoptosis induction
↑ anticancer effect
[225]
gefitinib + paclitaxel trilaurin, α-tocopherol, 1,2-distearoyl-sn-glycero-3-phosphocholine, (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000], luteinizing hormone release hormone 100–300 nm lung adenocarcinoma A549, H-1975, PC-9, PC-9GR cells ↑ anticancer effect [226]
imatinib Compritol® ATO 888, oleic acid, Gelucire® 48/16, Gelucire® 43/01, Span 80, Tween® 80 ca. 96 nm gastric adenocarcinoma CRL-1739 cells sustained release
↑ anticancer effect
[227]
imatinib stearic acid, sesame oil, sodium lauryl sulphate, Tween® 80 ca. 104 nm MCF-7 breast cancer cells ↑ anticancer effect [228]
sorafenib tripalmitin, Captex® 355 EP/NF <300 nm hepatocellular carcinoma HepG2, Hep3B, Huh7, PLC/PRF/5 cells sustained release
↑ cellular uptake
↑ anticancer effect
[229]
sunitinib Pluronic® F127, cholesterol, Labrafac™, biotin, stearylamine ca. 125 nm lung adenocarcinoma A549 cells sustained release (>8 h)
↑ cellular uptake
↑ anticancer effect
[230]
osimertinib stearic acid, Labrafil® M 1944CS, poloxamer 407 ca. 162 nm lung adenocarcinoma A549 cells sustained release
↑ permeation
↑ anticancer effect
[231]